EMG
NEOS

Ellington Management Group’s Neos Therapeutics, Inc NEOS Stock Holding History

Ellington Management Group’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-61,200
Closed -$447K – 929
2017
Q2 		$447K Buy
+61,200
New +$462K 0.06% 275

Other funds holding NEOS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ellington Management Group's NEOS Position: Q3 2017 in Review

Ellington Management Group sold out of Neos Therapeutics, Inc (NEOS) in Q3 2017, closing a stake of 61,200 shares — an estimated $447K sold.

Ellington Management Group first reported a position in NEOS in Q2 2017 and held it in 1 quarter. The position peaked at $447K in Q2 2017. 63 funds tracked by Wall St. Rank hold NEOS as of Q3 2017.

  • Ellington Management Group reported no remaining Neos Therapeutics, Inc position as of Q3 2017 after selling out during the quarter.
  • Ellington Management Group sold 61,200 Neos Therapeutics, Inc shares in Q3 2017, an estimated $447K.
  • Ellington Management Group first reported a position in Neos Therapeutics, Inc in Q2 2017 and held it in 1 quarter.
  • Ellington Management Group's Neos Therapeutics, Inc position peaked at $447K in Q2 2017.
  • 63 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q3 2017.

Based on Ellington Management Group's 13F filing for Q3 2017, filed 14 Nov 2017.